Literature DB >> 21689705

Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses.

Ying Yin1, Hao Li, Shipo Wu, Dayong Dong, Jun Zhang, Ling Fu, Junjie Xu, Wei Chen.   

Abstract

Early secreted antigenic target-6 (ESAT-6), an important Mycobacterium tuberculosis T-cell antigen, is an attractive candidate antigen for tuberculosis subunit vaccine development. Because ESAT-6 has a low inherent immunogenicity, we used Hepatitis B virus core (HBc) protein as an immune carrier to enhance ESAT-6 immunogenicity. The ESAT-6 gene was inserted into the major immunodominant region of the HBc molecule by fusion PCR. The recombinant protein, HBc-ESAT-6 (HE6), was expressed in Escherichia coli, and electron microscopy confirmed the formation of virus-like particles. The immunogenicity of the chimeric particles was assessed in mice. Serological assays and in vitro Th1-biased cytokine assays found that immunization with HE6 particles elicited significantly higher ESAT-6-specific antibodies and CD4⁺/CD8⁺ T cell responses in mice compared to immunization with recombinant ESAT-6 protein. These data demonstrate the feasibility of HBc particles serving as an efficient immune carrier for ESAT-6 and suggest that HE6 has potential for use in a tuberculosis subunit vaccine.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689705     DOI: 10.1016/j.vaccine.2011.06.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

Review 2.  Bioengineering Strategies for Protein-Based Nanoparticles.

Authors:  Dennis Diaz; Andrew Care; Anwar Sunna
Journal:  Genes (Basel)       Date:  2018-07-23       Impact factor: 4.096

3.  Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles.

Authors:  Dhananjayan Dhanasooraj; R Ajay Kumar; Sathish Mundayoor
Journal:  Int J Nanomedicine       Date:  2013-02-25

Review 4.  Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development.

Authors:  William A Rodríguez-Limas; Karthik Sekar; Keith E J Tyo
Journal:  Curr Opin Biotechnol       Date:  2013-03-05       Impact factor: 9.740

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.